CORD-19:185e78aee848db9cc3a4510619048a6e4acd22cc / 347-849 JSONTXT

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T4","span":{"begin":0,"end":502},"obj":"Sentence"}],"text":"The ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) is currently the most widely used front-line treatment for patients with early and advanced stage cHL, with no alternative regimen to date showing superior overall survival (OS). [1] [2] [3] Patients with human immunodeficiency virus (HIV) infection have an 11-fold increased risk for cHL, 4 and cHL is driven by the Epstein-Barr virus (EBV) in approximately 40% of cases, including nearly all cases associated with HIV infection."}

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T4","span":{"begin":0,"end":502},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":0,"end":502},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) is currently the most widely used front-line treatment for patients with early and advanced stage cHL, with no alternative regimen to date showing superior overall survival (OS). [1] [2] [3] Patients with human immunodeficiency virus (HIV) infection have an 11-fold increased risk for cHL, 4 and cHL is driven by the Epstein-Barr virus (EBV) in approximately 40% of cases, including nearly all cases associated with HIV infection."}

{"project":"Epistemic_Statements","denotations":[{"id":"T1","span":{"begin":251,"end":502},"obj":"Epistemic_statement"}],"text":"The ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) is currently the most widely used front-line treatment for patients with early and advanced stage cHL, with no alternative regimen to date showing superior overall survival (OS). [1] [2] [3] Patients with human immunodeficiency virus (HIV) infection have an 11-fold increased risk for cHL, 4 and cHL is driven by the Epstein-Barr virus (EBV) in approximately 40% of cases, including nearly all cases associated with HIV infection."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T8","span":{"begin":170,"end":173},"obj":"Disease"},{"id":"T9","span":{"begin":283,"end":299},"obj":"Disease"},{"id":"T10","span":{"begin":312,"end":321},"obj":"Disease"},{"id":"T11","span":{"begin":357,"end":360},"obj":"Disease"},{"id":"T12","span":{"begin":368,"end":371},"obj":"Disease"},{"id":"T13","span":{"begin":488,"end":501},"obj":"Disease"},{"id":"T14","span":{"begin":492,"end":501},"obj":"Disease"}],"attributes":[{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0009348"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0021094"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0009348"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0009348"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005109"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"The ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) is currently the most widely used front-line treatment for patients with early and advanced stage cHL, with no alternative regimen to date showing superior overall survival (OS). [1] [2] [3] Patients with human immunodeficiency virus (HIV) infection have an 11-fold increased risk for cHL, 4 and cHL is driven by the Epstein-Barr virus (EBV) in approximately 40% of cases, including nearly all cases associated with HIV infection."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T6","span":{"begin":283,"end":299},"obj":"Phenotype"}],"attributes":[{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0002721"}],"text":"The ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) is currently the most widely used front-line treatment for patients with early and advanced stage cHL, with no alternative regimen to date showing superior overall survival (OS). [1] [2] [3] Patients with human immunodeficiency virus (HIV) infection have an 11-fold increased risk for cHL, 4 and cHL is driven by the Epstein-Barr virus (EBV) in approximately 40% of cases, including nearly all cases associated with HIV infection."}